

# Comparative Effects of Valsartan Versus Amlodipine on Left Ventricular Mass and Reactive Oxygen Species Formation by Monocytes in Hypertensive Patients With Left Ventricular Hypertrophy

Kenichi Yasunari, MD, PHD, Kensaku Maeda, MD, Takanori Watanabe, MD, Munchiro Nakamura, MD, Junichi Yoshikawa, MD, PHD, FACC, Akira Asada, MD, PHD

Osaka, Japan

---

<b>OBJECTIVES</b>	To compare the effects of the angiotensin receptor blocker (ARB) valsartan versus the calcium channel blocker amlodipine, reactive oxygen species (ROS) formation by monocytes, C-reactive protein (CRP), and left ventricular (LV) mass were studied in 104 hypertensive patients with left ventricular hypertrophy (LVH).
<b>BACKGROUND</b>	There is evidence that ARBs have blood pressure (BP)-independent effects on LV mass. Whether regression of LV mass by ARBs is correlated to ROS formation by monocytes and CRP is not fully understood yet.
<b>METHODS</b>	A cross-sectional and prospective study was performed. Participants were randomly assigned to either the 80-mg valsartan (n = 52) or 5-mg amlodipine (n = 52) group and were treated for eight months. The left ventricular mass index (LVMI) was calculated from two-dimensional M-mode echocardiography. Formation of ROS by monocytes was measured by gated flow cytometry. In addition, CRP, plasma renin activity, plasma aldosterone, and traditional risk factors were assessed.
<b>RESULTS</b>	Multiple regression analysis showed a significant correlation between LVMI and ROS formation by monocytes and between LVMI and CRP. Treatment reduced BP to a similar extent in both groups. Valsartan significantly reduced LVMI after eight months, but amlodipine had less effect (16% vs. 1.2%, n = 50, p < 0.01). Formation of ROS by monocytes was reduced to a greater extent with valsartan than with amlodipine (28% vs. 2%, n = 50, p < 0.01). Valsartan but not amlodipine reduced CRP levels. A significant correlation between changes in ROS formation by monocytes and LVMI or between CRP and LVMI was observed.
<b>CONCLUSIONS</b>	The ARB valsartan has BP-independent effects on LVH, ROS formation by monocytes, and CRP in hypertensive patients with LVH. (J Am Coll Cardiol 2004;43:2116–23) © 2004 by the American College of Cardiology Foundation

---

Left ventricular hypertrophy (LVH), the most common cardiac consequence of hypertension, is a strong risk factor for cardiovascular complications and morbidity (1,2). In addition to pressure load, LVH appears to be modified by genetic and humoral factors (3,4). Among the most important of such factors is the renin-angiotensin system (5,6). Angiotensin II (ATII) is a powerful stimulator of myocyte growth, and many studies have shown the relationship between plasma ATII and LVH in essential hypertension (7,8).

There is evidence for increased inflammation in some patients with essential hypertension. Evidence for increased inflammation includes increased reactive oxygen species

(ROS) formation by monocytes (9) and increased levels of plasma C-reactive protein (CRP) (10). Increased intracellular ROS formation by monocytes can lead to increased expression of cell surface adhesion molecules, which are regarded as markers of inflammation (11). Recently, we demonstrated the relationship between CRP and ROS formation by monocytes (12). It has been reported that CRP stimulates interleukin (IL)-6 release from monocytes (13) and that continuous activation of the IL-6 receptor induces myocardial hypertrophy in mice (14).

Angiotensin receptor blockers (ARBs) are a well-established form of antihypertensive therapy and have recently been shown to have benefits beyond blood pressure (BP) reduction—for example, in microalbuminuria in diabetic subjects (15). In the Losartan Intervention For Endpoint reduction (LIFE) trial (16), the ARB losartan had greater effects on LVH than the comparator substance atenolol for the same reduction in BP. To our knowledge, no study has investigated the possible involvement of

---

From the Department of General Medicine and Cardiology, Graduate School of Medicine, Osaka City University, Osaka, Japan. This study was supported by the Ministry of Education, Sports, Science, and Technology, the Takeda Science Foundation, the Kimura Memorial Heart Foundation, the Research Foundation of Community Medicine, and the Japan Research Foundation for Clinical Pharmacology.

Manuscript received October 1, 2003; revised manuscript received December 9, 2003, accepted December 15, 2003.

**Abbreviations and Acronyms**

ARB	=	angiotensin receptor blocker
ATII	=	angiotensin II
BP	=	blood pressure
CDCFH bis-AM ester	=	carboxydichlorofluorescein diacetate bis-acetoxymethyl ester
CRP	=	C-reactive protein
IL	=	interleukin
LV	=	left ventricular
LVH	=	left ventricular hypertrophy
LVMI	=	left ventricular mass index
ROS	=	reactive oxygen species

inflammatory markers such as ROS formation by monocytes or CRP in an ATII-mediated increase in LV mass.

In the present study, we compared the changes in LVH and the changes in inflammatory markers such as monocyte ROS formation and levels of CRP caused by treatment with the ARB valsartan or the calcium channel blocker amlodipine. The possible involvement of inflammatory markers in an ATII-mediated increase in LV mass in hypertensive patients was also studied.

**METHODS**

**Participants.** This study consisted of two phases: a cross-sectional analysis of the relationship between the left ventricular mass index (LVMI) and risk of LVH, as well as a prospective, randomized, double-blinded study of hypertensive subjects with LVH who visited Osaka City University Hospital from April 1999 to April 2002. The primary outcome was the change in LVH associated with treatment, and the secondary outcome was the change in inflammatory markers such as oxidative stress in monocytes and CRP associated with treatment. The relationship between LVH and inflammatory markers was also studied.

Subjects who had not been treated for hypertension or who had discontinued antihypertensive agents and who had a BP of  $\geq 140/90$  mm Hg after a double-blinded, four-week placebo run-in period were included in the trial. During the run-in period, the presence of LVH was established by echocardiography and defined as LVMI  $>134$  g/m<sup>2</sup> for men and  $>110$  g/m<sup>2</sup> for women and/or septal thickness  $>12$  mm at end diastole (17). None of the subjects were taking any medications, including nonsteroidal anti-inflammatory drugs, vitamin E, or other antioxidants. Randomization was performed by a controller who did not know the results and was using a computer-generated random allocation sequence in a numbered container. The subjects were given oral 80 mg of valsartan or the calcium channel blocker amlodipine (5 mg) for eight months. The protocol was approved by the Institutional Review Board of Osaka City University. Written, informed consent was obtained from all subjects.

Systolic and diastolic BPs were recorded as the average of the second and third rest period, seated, cuff BP measurements, in systole and diastole, respectively, measured after a 5-min rest period. Fasting blood samples were collected, and echocardiography was performed at baseline and at month 8. Obesity was estimated in terms of body mass index. Plasma insulin, plasma glucose, glycosylated hemoglobin, plasma cholesterol, triglyceride, high-density lipoprotein cholesterol, plasma renin and aldosterone concentrations were measured in venous blood. Serum CRP was measured by latex-enhanced immunonephelometric assay on a BN II analyzer (Dade Behring, Newark, Delaware), a highly sensitive technique.

**Assay of ROS formation by monocytes.** Formation of ROS by monocytes was measured using a gated flow cytometric technique, as described in previous studies (18,19), with some modifications (11). Fresh blood (1 ml) was collected from participants into preservative-free heparin (10 U/ml blood). The blood was pre-incubated for 15

**Table 1.** Baseline Characteristics of Hypertensive Patients

	Valsartan Group (n = 52)	Amlodipine Group (n = 52)	p Value*
Age (yrs)	62 ± 11	64 ± 12	0.6
Gender (M/F)	31/21	31/21	1.0
Body mass index (kg/m <sup>2</sup> )	24.1 ± 3.8	24.3 ± 2.8	0.8
Systolic BP (mm Hg)	152 ± 8	152 ± 6	1.0
Diastolic BP (mm Hg)	93 ± 5	92 ± 6	0.4
ROS formation by monocytes (arbitrary units)	91 ± 20	86 ± 24	0.3
C-reactive protein (mg/dl)	0.10 (0.10–0.30)	0.10 (0.05–0.20)	1.0
LVMI (g/m <sup>2</sup> )	166 ± 29	161 ± 39	0.5
Glycosylated hemoglobin (%)	5.4 ± 0.5	5.4 ± 1.0	1.0
Triglyceride (mg/dl)	113 ± 59	127 ± 85	0.3
HDL cholesterol (mg/dl)	53 ± 13	54 ± 13	0.7
LDL cholesterol (mg/dl)	118 ± 26	114 ± 34	0.5
Renin (ng/ml/h)	1.67 ± 2.25	1.83 ± 3.45	0.8
Aldosterone (pg/ml)	10.1 ± 3.9	11.7 ± 7.7	0.2

\*Computed with the Mann-Whitney U test. Data are presented as the mean value ± SD, except for C-reactive protein, expressed as the median value (interquartile range).

BP = blood pressure; HDL and LDL = high- and low-density lipoprotein, respectively; LVMI = left ventricular mass index; ROS = reactive oxygen species.

**Table 2.** Multiple Regression Analysis of the Relationship Between Left Ventricular Mass Index and Other Variables for the Entire Group

Variables	Regression Coefficient	Standard Error	Standardized Regression Coefficient	p Value
Age (yrs)	-0.12	0.31	-0.04	0.70
Gender (female)	-8.42	6.96	-0.12	0.23
Body mass index (kg/m <sup>2</sup> )	2.39	1.03	0.23	0.02
Systolic BP (mm Hg)	1.01	0.48	0.21	0.04
Diastolic BP (mm Hg)	-0.67	0.60	-0.11	0.26
Glycosylated hemoglobin (%)	-6.45	4.17	-0.15	0.13
Triglycerides (mg/dl)	-0.03	0.05	-0.06	0.54
HDL cholesterol (mg/dl)	-0.18	0.29	-0.07	0.55
LDL cholesterol (mg/dl)	-0.03	0.11	-0.02	0.83
C-reactive protein (mg/dl)	21.71	10.23	0.20	0.04
ROS formation by monocytes (arbitrary units)	0.45	0.15	0.29	<0.01
Renin (ng/ml/h)	2.17	1.12	0.19	0.06
Aldosterone (pg/ml)	-0.33	0.58	-0.06	0.57

The dependent variable is left ventricular mass index. Independent variables are age, gender, systolic BP, diastolic BP, glycosylated hemoglobin, triglycerides, HDL cholesterol, LDL cholesterol, C-reactive protein, ROS formation by monocytes, renin, and aldosterone.


Abbreviations as in Table 1.

min with 2',7'-carboxydichlorofluorescein diacetate bis-acetoxymethyl ester (CDCFH bis-AM ester) (100 μmol/l) in a 37°C water bath with gentle horizontal shaking. The CDCFH bis-AM ester is a nonpolar compound that is converted into a nonfluorescent polar derivative (CDCFH) by cellular esterases after incorporation into cells. CDCFH is membrane-impermeable and rapidly oxidized to the highly fluorescent carboxydichlorofluorescein in the presence of intracellular hydrogen peroxide and peroxidase. Red blood cells were lysed, and white blood cells were suspended in 1% paraformaldehyde/phosphate-buffered saline. The fixed samples were kept on ice until flow cytometric analysis on the same day. Formation of ROS by monocytes was measured as the fluorescence intensity by gated flow cytometry. The coefficients of variation of the intra- and inter-assays were 6.6% and 10.2%, respectively.

**Echocardiography.** Two-dimensional directed and guided M-mode echocardiographic studies were performed in all participants by one experienced investigator. The investigator reading the echocardiograms was blinded as to the treatment group. The LV mass was measured on the M-mode guided echocardiogram, according to the method recommended by the American Society of Echocardiography (20). Left ventricular mass was derived from the formula described by Devereux et al. (17):

$$\text{LV mass (g)} = 0.80 \times 1.04 ([\text{VSTd} + \text{LVIDd} + \text{PWTd}]^3 - [\text{LVIDd}]^3) + 0.6$$

where VSTd is the end-diastolic ventricular septal thickness; LVIDd is the LV end-diastolic internal dimension; and PWTd is the LV end-diastolic posterior wall thickness.



**Figure 1.** Relationships between reactive oxygen species (ROS) formation by monocytes (MNCs) and left ventricular mass index (LVMI) and between C-reactive protein (CRP) and LVMI (n = 104).

**Table 3.** Changes in Measurements From Baseline to Six Months

	Valsartan Group (n = 50)			Amlodipine Group (n = 50)			p Value (Intergroup)
	Difference	95% CI	p Value (Intragroup)	Difference	95% CI	p Value (Intragroup)	
Body mass index (kg/m <sup>2</sup> )	0.2	(0 to 0.3)	0.4	0.2	(0 to 0.5)	0.1	1.00
Systolic BP (mm Hg)	-12	(-14 to -10)	<0.01	-11	(-13 to -9)	<0.01	0.48
Diastolic BP (mm Hg)	-7	(-8 to -6)	<0.01	-8	(-10 to -5)	<0.01	0.52
Monocyte oxidative stress (arbitrary units)	-26	(-31 to -21)	<0.01	-7	(-15 to 2)	0.1	<0.01
C-reactive protein (mg/dl)	-0.14	(-0.22 to -0.07)	<0.01	0.01	(-0.04 to 0.06)	0.9	<0.01
LVMI (g/m <sup>2</sup> )	-28	(-35 to -21)	<0.01	-3	(-7 to 1)	0.1	<0.01
Glycosylated hemoglobin (%)	0	(-0.1 to 0.1)	1.0	0.1	(0 to 0.2)	0.3	0.16
Triglycerides (mg/dl)	1	(-11 to 12)	0.9	-10	(-29 to 10)	0.3	0.27
HDL cholesterol (mg/dl)	-1	(-3 to 1)	0.2	-1	(-3 to 1)	0.2	1.00
LDL cholesterol (mg/dl)	-2	(-8 to 4)	0.5	-5	(-10 to 1)	0.1	0.48
Renin (ng/ml/h)	0.4	(-0.1 to 1.0)	0.1	0	(-0.7 to 0.7)	0.9	0.19
Aldosterone (pg/ml)	-0.5	(-1.5 to 0.5)	0.3	-1	(-2.6 to 0.6)	0.2	0.59


CI = confidence interval; other abbreviations as in Table 1.

**Statistical analysis.** All data are expressed as the mean value  $\pm$  SD, unless otherwise specified. Statistical analyses were performed using Statview 5.0 and JMP 4.0 (SAS Institute, Cary, North Carolina). Statistical analysis of the results for intergroup comparisons was performed with the Student *t* test preceded by an *F* test. A comparison of measurements at baseline and six months later was carried out by the paired *t* test (two-sided *p* value and 95% confidence interval [CI]). C-reactive protein was expressed as the median value (interquartile range), and *p* values were computed by the Mann-Whitney *U* test for intergroup comparisons at baseline. The relationship between LVMI


and relevant covariates was examined by determination of standardized correlation coefficients and linear regression analysis.

## RESULTS

**Baseline characteristics.** During the four-week run-in period, among the 120 patients who underwent randomization, 16 participants withdrew because they became normotensive. Two patients in each treatment group discontinued the study because of adverse events. In the valsartan group, liver dysfunction (*n* = 1) and headache (*n* = 1) were



**Figure 2.** Effect of valsartan (*n* = 50) and amlodipine (*n* = 50) on left ventricular mass index (LVMI). The open circles on the vertical bars represent the mean value  $\pm$  SD. *p* < 0.01 for baseline versus six months later in the valsartan group; *p* < 0.01 for baseline versus six months later in the amlodipine group.



**Figure 3.** Effect of valsartan (n = 50) and amlodipine (n = 50) on reactive oxygen species (ROS) formation by monocytes (MNCs). The open circles on the vertical bars represent the mean  $\pm$  SD.  $p < 0.01$  for baseline versus six months later in the valsartan group;  $p = 0.1$  for baseline versus six months later in the amlodipine group.


observed. In the amlodipine group, tachycardia (n = 1) and pretibial edema (n = 1) were observed.

Baseline characteristics in each treatment group are shown in Table 1. Subjects were well matched for age, body mass index, BP, gender, glycosylated hemoglobin, triglycerides, and cholesterol. There were no significant differences between the values for LVMI, CRP, and ROS formation by monocytes.


At baseline, multiple regression analysis was used to quantify the correlation of measured variables to LVMI. The results of the analysis are shown in Table 2. Formation

of ROS by monocytes was significantly related to LVMI ( $r = 0.29$ ,  $p < 0.01$ ), and there was a significant correlation between CRP, systolic BP, and body mass index with LVMI (for CRP:  $r = 0.20$ ,  $p = 0.04$ ; systolic BP:  $r = 0.21$ ,  $p = 0.04$ ; body mass index:  $r = 0.23$ ,  $p = 0.02$ ). The relationships between oxidative stress in monocytes and LVMI and between CRP and LVMI are also shown in Figure 1.

**Changes in BP.** Both valsartan and amlodipine treatment reduced BP to a similar extent. In the valsartan group,



**Figure 4.** Relationships between the decrease ( $\Delta$ ) in reactive oxygen species (ROS) formation by monocytes (MNCs) and the decrease in left ventricular mass index (LVMI) and between the decrease in C-reactive protein (CRP) and the decrease in LVMI in the valsartan-treated group (n = 50).



**Figure 5.** Effect of valsartan (n = 50) and amlodipine (n = 50) on C-reactive protein levels. The **open circles on the vertical bars** represent the mean value  $\pm$  SD.  $p < 0.01$  for baseline versus six months later in the valsartan group;  $p = 0.7$  for baseline versus six months later in the amlodipine group.

systolic BP fell from  $152 \pm 8$  mm Hg to  $140 \pm 7$  mm Hg and diastolic BP fell from  $93 \pm 5$  mm Hg to  $86 \pm 5$  mm Hg. The reductions in the amlodipine group were from  $152 \pm 6$  mm Hg to  $140 \pm 6$  mm Hg for systolic BP and from  $92 \pm 6$  mm Hg to  $84 \pm 5$  mm Hg for diastolic BP. At the end of the study, no intergroup difference in systolic and diastolic BP was observed (Table 3).

**LVMI.** Despite the very similar effects on BP, there were highly significant differences between valsartan and amlodipine treatment on LVMI (Table 1, Fig. 2). In the valsartan group, LVMI decreased from  $166 \pm 29$  g/m<sup>2</sup> to  $137 \pm 26$  g/m<sup>2</sup>, representing a mean decrease of  $16 \pm 13\%$  ( $p < 0.01$ ) (Fig. 3, Table 3). In contrast, amlodipine had a lesser effect on LVMI, which was reduced from  $161 \pm 39$  g/m<sup>2</sup> to  $158 \pm 37$  g/m<sup>2</sup>, a mean decrease of  $1.2 \pm 8.1\%$  ( $p = 0.14$ ) (Fig. 3, Table 3). The greater reduction in LVMI with valsartan compared with amlodipine was statistically significant ( $p < 0.01$ ) (Table 3).

**Formation of ROS by monocytes.** As with LVMI, there were marked differences between the effects of the two treatments on ROS formation by monocytes. In the valsartan group, ROS formation by monocytes was reduced from  $91 \pm 20$  to  $65 \pm 18$  arbitrary units, representing a mean decrease of  $28 \pm 16\%$  ( $n = 50$ ,  $p < 0.01$ ) (Fig. 3, Table 3). In the amlodipine group, ROS formation by monocytes was reduced from  $86 \pm 24$  to  $80 \pm 25$  arbitrary units, a mean decrease of  $2 \pm 39\%$  ( $n = 50$ ,  $p = 0.11$ ) (Fig. 3, Table 3). The greater reduction in ROS formation by monocytes with valsartan compared with amlodipine was statistically significant ( $p < 0.01$ ) (Table 3). Linear regression analysis

showed a significant correlation between the decrease in LVMI and the decrease in ROS formation by monocytes in the valsartan group ( $r = 0.61$ ,  $p < 0.01$ ) (Fig. 4), but not in the amlodipine group ( $r = 0.54$ ,  $p = 0.59$ ).

**CRP.** In the valsartan group, CRP levels were reduced significantly, from  $0.10$  (95% CI  $0.10$  to  $0.30$ ) to  $0.08$  (95% CI  $0.05$  to  $0.10$ ) mg/dl, a mean decrease of  $39 \pm 26\%$  ( $p < 0.01$ ) (Fig. 5, Table 3). In contrast, there were no reductions in CRP levels in the amlodipine group (baseline:  $0.10$  mg/dl [95% CI  $0.05$  to  $0.20$ ]; month 8:  $0.05$  mg/dl [95% CI  $0.05$  to  $0.20$ ];  $p = 0.94$ ) (Fig. 5, Table 3). There was a significant correlation between the decrease in CRP and the decrease in LVMI in the valsartan group ( $r = 0.46$ ,  $p < 0.01$ ) (Fig. 4), but not in the amlodipine group ( $r = 0.54$ ,  $p = 0.89$ ). The greater reduction in CRP with valsartan compared with amlodipine was statistically significant ( $p < 0.01$ ) (Table 3). In the valsartan group, there was also a significant correlation between the reduction in CRP and the decrease in ROS formation by monocytes ( $r = 0.38$ ,  $p < 0.01$ ), but no such correlation was observed in the amlodipine group ( $r = 0.54$ ,  $p = 0.62$ ).

**Other traditional risk factors.** We also examined the treatment-induced changes in other traditional risks factors, such as age, gender, body mass index, glycosylated hemoglobin, triglycerides, and high- and low-density lipoprotein cholesterol, which were measured at baseline and month 8 in both treatment groups. There were no differences in the baseline levels of these factors between the two groups (Table 1). None of these variables was affected significantly by treatment (Table 3).

## DISCUSSION

**Summary of results.** This study shows that significant differences exist between the effects of ARB with valsartan and calcium channel blockade with amlodipine on LV mass, CRP, and ROS formation by monocytes, and that these effects were unrelated to the effects on BP. Both valsartan and amlodipine produced similar reductions in BP, but the reductions in LVMI (primary outcome) and inflammatory markers such as ROS formation by monocytes and CRP (secondary outcome) were significantly greater with valsartan treatment (Table 3). There were significant correlations at baseline between LVMI and ROS formation by monocytes and between LVMI and CRP, as well as between decreases in the levels of these substances and regression of LVMI.

**Effect of valsartan on monocyte oxidative stress and LV mass.** In the present study, we found that valsartan inhibited ROS formation by monocytes. It has been previously reported that ATII receptors are expressed in monocytes and that ATII increases ROS formation by monocytes (21). Locally produced ATII might be involved in this increase (5,6). However, in the present study, we can only conclude that endogenous ATII may increase ROS formation by monocytes.

The precise mechanism of ROS formation by monocytes in conjunction with cardiomyocytes and LV mass alteration remains to be elucidated. However, a multiple regression analysis indicated that there is a significant correlation between ROS formation by monocytes and LV mass (Fig. 1, Table 2). In the valsartan group, the reduction in LVMI correlated with the reduction in ROS formation by monocytes (Fig. 4), which suggests that the ATII-induced ROS formation by monocytes may be one of the major causes of increased LV mass in patients with essential hypertension, apart from the increases in LV mass usually attributed to elevated BP. Valsartan has been found to have an antioxidative effect (22), and it has been reported that increased ROS formation by monocytes increases cytokine production, including IL-6 (13), which may cause myocardial hypertrophy (14). Hence, reduced ROS formation by monocytes with valsartan treatment may result in reduced IL-6 production and a corresponding decrease in LVH. In fact, it has been reported that IL-6 production is decreased by valsartan (23).

**Effect of valsartan on CRP and LV mass.** The most conspicuous differences between the two therapies in the present study were their effects on CRP levels. The CRP reduction with valsartan treatment was significantly greater than that with amlodipine (Table 3). We also observed that the decrease in CRP in the valsartan group significantly correlated to the decrease in LVMI (Fig. 4). C-reactive protein has a direct modulatory effect on monocytes, which promote IL-6 release (13) and may cause cardiac hypertrophy (14). Thus, ATII may interact with CRP, or monocytes, and thus cause hypertrophy.

It is interesting to note that studies with the ARBs losartan and candesartan in patients with coronary artery disease recently reported no effects on CRP levels from treatment (24,25). Whether this is due to differences in study design or differences between the ARBs remains to be established. However, it should be pointed out that some patients in the present study had severe LVH. In such patients, the cardiac renin-angiotensin system may be enhanced (26), which may exacerbate the inflammatory response, including CRP.

**Study limitations.** A limitation of the present study that may be considered significant is a possible bias due to patient selection. Some patients in the present study had severe LVH. This may call into question the applicability of the results to other patient populations.

**Conclusions.** The ARB valsartan seems to have effects on CRP, ROS formation by monocytes, and LVMI, unrelated to a reduction in BP. There were also significant correlations at baseline between LVMI and ROS formation by monocytes and between LVMI and CRP, as well as between decreases in the levels of these substances and regression of LVMI, suggesting the possible involvement of inflammatory response such as ROS formation by monocytes and CRP in an ATII-mediated increase in LV mass in hypertensive patients.

## Acknowledgments

We thank Yukiko Tainaka, Yuka Nishimura, and Sayuri Takagi for their excellent secretarial assistance.

---

**Reprint requests and correspondence:** Dr. Kenichi Yasunari, Department of General Medicine and Cardiology, Graduate School of Medicine, Osaka City University, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. E-mail: yasunari@med.osaka-cu.ac.jp.

---

## REFERENCES

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. *N Engl J Med* 1990;322:1561-6.
2. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. *Ann Intern Med* 1991;114:345-52.
3. Schunkert H, Hense HW, Holmer SR, et al. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. *N Engl J Med* 1994;330:1634-8.
4. Tarazi RC, Sen S, Saragoca M, Khairallah P. The multifactorial role of catecholamines in hypertensive cardiac hypertrophy. *Eur Heart J* 1982;3:103-10.
5. Morgan HE, Baker KM. Cardiac hypertrophy: mechanical, neural, and endocrine dependence. *Circulation* 1991;83:13-25.
6. Lindpaintner K, Ganten D. The cardiac renin-angiotensin system: an appraisal of present experimental and clinical evidence. *Circ Res* 1991;68:905-21.
7. Schmieder RE, Langenfeld MR, Friedrich A, Schobel HP, Gatzka CD, Weihprecht H. Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. *Circulation* 1996;94:1304-9.
8. Thürmann PA, Kenedi P, Schmidt A, Schmidt A, Harder S, Rietbrock N. Influence of the angiotensin II antagonist valsartan on left

- ventricular hypertrophy in patients with essential hypertension. *Circulation* 1998;98:2037-42.
9. Dorffel Y, Latsch C, Stuhlmuller B, Schreiber S, Scholze S. Preactivated peripheral blood monocytes in patients with essential hypertension. *Hypertension* 1999;34:113-7.
  10. Chul Sung K, Suh JY, Kim BS, et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. *Am J Hypertens* 2003;16:429-33.
  11. Alexander RW. The Jeremiah Metzger Lecture. Pathogenesis of atherosclerosis: redox as a unifying mechanism. *Trans Am Clin Climatol Assoc* 2003;114:273-304.
  12. Yasunari K, Maeda K, Nakamura M, Yoshikawa J. Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reactive protein. *Hypertension* 2002;39:777-80.
  13. Li JJ, Chen XJ. Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide. *Coron Artery Dis* 2003;14:329-34.
  14. Hirota H, Yoshida K, Kishimoto T, et al. Continuous activation of gp 130, signal-transducing receptor component for interleukin-6-related cytokines, cause myocardial hypertrophy in mice. *Proc Natl Acad Sci USA* 1995;92:4862-6.
  15. Viberti G, Wheeldon NM, for the MARVAL Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure independent effect. *Circulation* 2002;106:672-8.
  16. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002;359:995-1003.
  17. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. *Am J Cardiol* 1986;57:450-8.
  18. Yasunari K, Kohno M, Kano H, Yokokawa K, Minami M, Yoshikawa J. Antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose. *Circulation* 1999;99:1370-8.
  19. Yasunari K, Kohno M, Kano H, Minami M, Yoshikawa J. Dopamine as a novel antioxidative agent for rat vascular smooth muscle cells through dopamine D(1)-like receptors. *Circulation* 2000;101:2302-8.
  20. Sahn DJ, DeMaria A, Kisslo J, Weyma A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. *Circulation* 1978;58:1072-83.
  21. Yanagitani Y, Rakugi H, Okamura A, et al. Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. *Hypertension* 1999;33:335-9.
  22. Cheng ZJ, Vaskonen T, Tikkanen I, et al. Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats. *Hypertension* 2001;37:433-9.
  23. Peeters AC, Netea MG, Kullberg BJ, Thien T, van der Meer JW. The effect of renin-angiotensin system inhibitors on pro- and anti-inflammatory cytokine production. *Immunology* 1998;94:376-9.
  24. Prasad A, Koh KK, Schenke WH, et al. Role of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosis. *Am Heart J* 2001;142:248-53.
  25. Koh KK, Ahn JY, Han SH, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. *J Am Coll Cardiol* 2003;42:905-10.
  26. Kojima M, Shiojima I, Yamazaki T, et al. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signalling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. *Circulation* 1994;89:2204-11.